litlas
Log inCreate account

David Lebwohl

Active 1987–2025

39
Papers
26,254
Citations
36
h-index
39
i10-index

Citations

Citations per year for David Lebwohl1987: 9 citations1988: 43 citations1989: 42 citations1990: 25 citations1991: 28 citations1992: 16 citations1993: 11 citations1994: 10 citations1995: 12 citations1996: 16 citations1997: 12 citations1998: 14 citations1999: 16 citations2000: 18 citations2001: 11 citations2002: 13 citations2003: 20 citations2004: 27 citations2005: 50 citations2006: 44 citations2007: 66 citations2008: 70 citations2009: 133 citations2010: 133 citations2011: 194 citations2012: 217 citations2013: 310 citations2014: 288 citations2015: 242 citations2016: 240 citations2017: 205 citations2018: 257 citations2019: 816 citations2020: 878 citations2021: 874 citations2022: 825 citations2023: 644 citations2024: 972 citations2025: 516 citations2026: 28 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,766 citing papers, 30.1% of this breakdownChina: 1,057 citing papers, 8.5% of this breakdownGermany: 787 citing papers, 6.3% of this breakdownUnited Kingdom: 732 citing papers, 5.9% of this breakdownItaly: 716 citing papers, 5.7% of this breakdownFrance: 583 citing papers, 4.7% of this breakdownSpain: 442 citing papers, 3.5% of this breakdownCanada: 401 citing papers, 3.2% of this breakdownNetherlands: 342 citing papers, 2.7% of this breakdownJapan: 339 citing papers, 2.7% of this breakdownSwitzerland: 333 citing papers, 2.7% of this breakdownAustralia: 266 citing papers, 2.1% of this breakdown
0%30.1%Other 21.9%

Institutions

Fields

  • Medicine68.6%
  • Biochemistry, Genetics and Molecular Biology26.9%
  • Immunology and Microbiology2.1%
  • Materials Science0.4%
  • Chemistry0.3%
  • Engineering0.3%
  • Other1.4%

Topics

  • CAR-T cell therapy research11.3%
  • Virus-based gene therapy research4%
  • PI3K/AKT/mTOR signaling in cancer3.1%
  • Neuroendocrine Tumor Research Advances2.7%
  • CRISPR and Genetic Engineering2.7%
  • Nanowire Synthesis and Applications2.3%
  • Other73.9%

Coauthors

All papers

Open in search
  1. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

    Authors: Shannon L. Maude, Theodore W. Laetsch, Jochen Buechner, Susana Rives, Michael Boyer, Henrique Bittencourt, Peter Bader, Michael R. Verneris, Heather E. Stefanski, Gary D. Myers, Muna Qayed, Barbara De Moerloose, Hidefumi Hiramatsu, Krysta Schlis, Kara L. Davis, Paul L. Martin, Eneida R. Nemecek, Gregory A. Yanik, Christina Peters, André Baruchel, Nicolas Boissel, Françoise Méchinaud, Adriana Balduzzi, Joerg Krueger, Carl H. June, Bruce L. Levine, Patricia A. Wood, Tetiana Taran, Mimi Leung, Karen T. Mueller, Yiyun Zhang, Kapildeb Sen, David Lebwohl, Michael A. Pulsipher, Stephan A. Grupp - New England Journal of Medicine 2018 cited by 5,641

  2. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis

    Authors: Julian D. Gillmore, Ed Gane, Jörg Täubel, Justin Kao, Marianna Fontana, Michael L. Maitland, Jessica Seitzer, Daniel O’Connell, Kathryn Walsh, Kristy Wood, Jonathan D. Phillips, Yuanxin Xu, Adam Amaral, Adam P. Boyd, Jeffrey Cehelsky, Mark D. McKee, Andrew Schiermeier, Olivier Harari, Andrew Murphy, Christos A. Kyratsous, Brian Zambrowicz, Randy Soltys, David E. Gutstein, John P. Leonard, Laura Sepp‐Lorenzino, David Lebwohl - New England Journal of Medicine 2021 cited by 1,633

  3. Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

    Authors: José Baselga, Mario Campone, Martine Piccart, Howard A. Burris, Hope S. Rugo, Tarek Sahmoud, Shinzaburo Noguchi, Michael Gnant, Kathleen I. Pritchard, Fabienne Lebrun, J. Thaddeus Beck, Yoshinori Ito, Denise A. Yardley, Ines Deleu, Alejandra Perez, Thomas Bachelot, Luc Vittori, Zhiying Xu, Pabak Mukhopadhyay, David Lebwohl, Gabriel N. Hortobágyi - New England Journal of Medicine 2011 cited by 2,828

  4. CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema

    Authors: Hilary Longhurst, Karen Lindsay, Remy S. Petersen, Lauré M. Fijen, Padmalal Gurugama, David Maag, James S. Butler, Mrinal Y. Shah, A. Golden, Yuanxin Xu, Carri Boiselle, Joseph D Vogel, Ahmed M. Abdelhady, Michael L. Maitland, Mark D. McKee, Jessica Seitzer, Bo Han, Samantha Soukamneuth, John P. Leonard, Laura Sepp‐Lorenzino, Eliana D Clark, David Lebwohl, Danny M. Cohn - New England Journal of Medicine 2024 cited by 166

  5. Everolimus for Advanced Pancreatic Neuroendocrine Tumors

    Authors: James C. Yao, Manisha H. Shah, Tetsuhide Ito, C. Lombard Bohas, Edward M. Wolin, Eric Van Cutsem, Timothy J. Hobday, Takuji Okusaka, Jaume Capdevila, Elisabeth G.E. de Vries, Paola Tomassetti, Marianne Pavel, Sakina Hoosen, T Haas, Jeremie Lincy, David Lebwohl, Kjell Öberg - New England Journal of Medicine 2011 cited by 2,848

  6. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

    Authors: Robert J. Motzer, Bernard Escudier, Stéphane Oudard, Thomas E. Hutson, Camillo Porta, Sergio Bracarda, Viktor Grünwald, John A. Thompson, Robert A. Figlin, Norbert Hollaender, Gladys Urbanowitz, William J. Berg, Andrea Kay, David Lebwohl, Alain Ravaud - The Lancet 2008 cited by 3,012

  7. Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

    Authors: Denise A. Yardley, Shinzaburo Noguchi, Kathleen I. Pritchard, Howard A. Burris, José Baselga, Michael Gnant, Gabriel N. Hortobágyi, Mario Campone, Barbara Pistilli, Martine Piccart, Bohuslav Melichar, Katarína Petráková, Francis P. Arena, Frans Erdkamp, Wael A. Harb, Wentao Feng, Ayelet Cahana, Tetiana Taran, David Lebwohl, Hope S. Rugo - Advances in Therapy 2013 cited by 520

  8. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

    Authors: Marianne Pavel, John D. Hainsworth, Éric Baudin, Marc Peeters, Dieter Hörsch, Robert Winkler, Judith Klimovsky, David Lebwohl, Valentine Jehl, Edward M. Wolin, Kjell Öberg, Eric Van Cutsem, James C. Yao - The Lancet 2011 cited by 1,052

  9. CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy

    Authors: Marianna Fontana, Scott D. Solomon, Jessica Kachadourian, Liron Walsh, Ricardo Rocha, David Lebwohl, Derek K. Smith, Jörg Täubel, Edward Gane, Björn Pilebro, David J. Adams, Yousuf Razvi, Joy Olbertz, Alexandra Haagensen, Peijuan Zhu, Yuanxin Xu, Adia Leung, Alison Sonderfan, David E. Gutstein, Julian D. Gillmore - New England Journal of Medicine 2024 cited by 113

  10. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

    Authors: John J. Bissler, J.C. Kingswood, Elżbieta Radzikowska, Bernard A. Zonnenberg, Michael Frost, Е. Д. Белоусова, Matthias Sauter, Norio Nonomura, Susanne Brakemeier, Petrus J. de Vries, Vicky Whittemore, David Chen, Tarek Sahmoud, Gaurav Shah, Jeremie Lincy, David Lebwohl, Klemens Budde - The Lancet 2013 cited by 879

  11. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial

    Authors: David Neal Franz, Е. Д. Белоусова, Steven Sparagana, E. Martina Bebin, Michael Frost, Rachel Kuperman, Olaf Witt, Michael Kohrman, J. Robert Flamini, Joyce Y. Wu, Paolo Curatolo, Petrus J. de Vries, Vicky Whittemore, Elizabeth A. Thiele, James Ford, Gaurav Shah, Helene Cauwel, David Lebwohl, Tarek Sahmoud, Sergiusz Jóźwiak - The Lancet 2012 cited by 784

  12. Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From BOLERO-2

    Authors: Gabriel N. Hortobágyi, David Chen, Martine Piccart, Hope S. Rugo, Howard A. Burris, Kathleen I. Pritchard, Mario Campone, Shinzaburo Noguchi, Alejandra Perez, Ines Deleu, Mikhail Shtivelband, Norikazu Masuda, Shaker R. Dakhil, Ian C. Anderson, Douglas Robinson, Wei He, Abhishek D. Garg, E. Robert McDonald, Hans Bitter, Alan Huang, Tetiana Taran, Thomas Bachelot, Fabienne Lebrun, David Lebwohl, José Baselga - Journal of Clinical Oncology 2015 cited by 246

  13. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update

    Authors: David Lebwohl, Renzo Canetta - European Journal of Cancer 1998 cited by 752

  14. CRISPR-Based Therapy for Hereditary Angioedema

    Authors: Danny M. Cohn, Padmalal Gurugama, Markus Magerl, Constance H. Katelaris, David Launay, Laurence Bouillet, Remy S. Petersen, Karen Lindsay, Emel Aygören‐Pürsün, David Maag, James S. Butler, Mrinal Y. Shah, A. Golden, Yuanxin Xu, Ahmed M. Abdelhady, David Lebwohl, Hilary Longhurst - New England Journal of Medicine 2024 cited by 52

  15. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412

    Authors: Richard M. Stone, Daniel J. DeAngelo, Virginia M. Klimek, Ilene Galinsky, Eli Estey, Stephen D. Nimer, Wilson Grandin, David Lebwohl, Yanfeng Wang, Pamela Cohen, Edward A. Fox, Donna Neuberg, Jennifer Clark, D. Gary Gilliland, James D. Griffin - Blood 2004 cited by 660

  16. Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study

    Authors: Atsushi Ohtsu, Jaffer A. Ajani, Yu-Xian Bai, Yung‐Jue Bang, Hyun Cheol Chung, Hong-Ming Pan, Tarek Sahmoud, Lin Shen, Kun‐Huei Yeh, Keisho Chìn, Kei Muro, Yeul Hong Kim, David Ferry, Niall C. Tebbutt, Salah‐Eddin Al‐Batran, Heind Smith, Chiara Costantini, Syed Rizvi, David Lebwohl, Eric Van Cutsem - Journal of Clinical Oncology 2013 cited by 494

  17. Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2

    Authors: Michael Gnant, José Baselga, Hope S. Rugo, Shinzaburo Noguchi, Howard A. Burris, Martine Piccart, Gabriel N. Hortobágyi, Janice F. Eakle, Hirofumi Mukai, Hiroji Iwata, Matthias Geberth, Lowell L. Hart, Peyman Hadji, Mona El-Hashimy, Shantha Rao, Tetiana Taran, Tarek Sahmoud, David Lebwohl, Mario Campone, Kathleen I. Pritchard - JNCI Journal of the National Cancer Institute 2013 cited by 98

  18. Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK 222584, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma

    Authors: J. Randolph Hecht, Tanja Trarbach, John D. Hainsworth, Pierre Major, Elke Jäger, Robert A. Wolff, Katherine Lloyd-Salvant, G. Bodoky, Kelly Pendergrass, William J. Berg, Bee-Lian Chen, T. Jalava, Gerold Meinhardt, Dirk Laurent, David Lebwohl, David J. Kerr - Journal of Clinical Oncology 2011 cited by 175

  19. Prognostic and Predictive Role of Lactate Dehydrogenase 5 Expression in Colorectal Cancer Patients Treated with PTK787/ZK 222584 (Vatalanib) Antiangiogenic Therapy

    Authors: Michael I. Koukourakis, Alexandra Giatromanolaki, Efthimios Sivridis, Kevin C. Gatter, Tanja Trarbach, Gunnar Folprecht, Michael Shi, David Lebwohl, T. Jalava, Dirk Laurent, Gerold Meinhardt, Adrian L. Harris - Clinical Cancer Research 2011 cited by 131

  20. Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial

    Authors: James C. Yao, Catherine Lombard‐Bohas, Éric Baudin, Larry K. Kvols, Philippe Rougier, Philippe Ruszniewski, Sakina Hoosen, J. Peter, T Haas, David Lebwohl, Eric Van Cutsem, Matthew H. Kulke, Timothy J. Hobday, Thomas M. O’Dorisio, Manisha H. Shah, Guillaume Cadiot, Gabriele Luppi, James Posey, Bertram Wiedenmann - Journal of Clinical Oncology 2009 cited by 649

  21. Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

    Authors: Josep Tabernero, Federico Rojo, Emiliano Calvo, Howard A. Burris, Ian Judson, Katharine Hazell, Erika Martinelli, Santiago Ramón y Cajal, Suzanne F. Jones, Laura Vidal, Nicholas Shand, Teresa Macarulla, Francisco Javier Ramos, Saša Dimitrijević, Ulrike Zoellner, Pui Tang, Michael Stumm, Heidi A. Lane, David Lebwohl, José Baselga - Journal of Clinical Oncology 2008 cited by 532

  22. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy

    Authors: Ruirong Yuan, Andrea Kay, William J. Berg, David Lebwohl - Journal of Hematology & Oncology 2009 cited by 250

  23. Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases

    Authors: David Lebwohl, Özlem Anak, Tarek Sahmoud, Judith Klimovsky, Ingrid Elmroth, T Haas, Joseph A. Posluszny, Stephen Saletan, William J. Berg - Annals of the New York Academy of Sciences 2013 cited by 91

  24. Industry’s Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy

    Authors: Stacie Ittershagen, Solveig G. Ericson, Lamis Eldjerou, Ali Shojaee, Eric Bleickardt, Manisha Patel, Tetiana Taran, Oezlem Anak, Charlene Hall, Mimi Leung, Deborah Roccoberton, Florence Salmon, Miriam Fuchs, Vadim Romanov, David Lebwohl - Current Hematologic Malignancy Reports 2019 cited by 17